S. Hernesniemi

发表

Aberrant kinase activation as a therapy target : Chronic myeloid leukemia as a model disease

S. Hernesniemi, 2012 .

Wetting and Reactivity between Nitride Ceramics and Molten Copper and Silver Alloys

S. Hernesniemi, 2012 .

Clonal Expansion of T/NK-Cells during Tyrosine Kinase Inhibitor Dasatinib Therapy

S. Mustjoki, I. Dybedal, P. Kovanen, 2008 .

Induction of sustained deep molecular response in a patient with chronic-phase T315I-mutated chronic myeloid leukemia with interferon-α monotherapy

S. Mustjoki, T. Lion, K. Porkka, 2014, Leukemia & lymphoma.

Clever‐1/Stabilin‐1 regulates lymphocyte migration within lymphatics and leukocyte entrance to sites of inflammation

S. Goerdt, S. Jalkanen, M. Salmi, 2009, European journal of immunology.

A novel dasatinib-sensitive RCSD1-ABL1 fusion transcript in chemotherapy-refractory adult pre-B lymphoblastic leukemia with t(1;9)(q24;q34)

S. Mustjoki, K. Porkka, A. Rauhala, 2009, Haematologica.

Rapid mobilization of cytotoxic lymphocytes induced by dasatinib therapy

S. Mustjoki, S. Hautaniemi, S. Jalkanen, 2013, Leukemia.

Impact of malignant stem cell burden on therapy outcome in newly diagnosed chronic myeloid leukemia patients

U. Olsson‐Strömberg, S. Mustjoki, T. Fioretos, 2013, Leukemia.

Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy

S. Mustjoki, M. Höglund, I. Dybedal, 2008, Leukemia.